Time course of IRF1 and IFITM3 RNA and protein expression across conditions. by Tyron Chang (9922533)

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

Characterization of the impact of glucose/galactose on infection outcomes. by Tyron Chang (9922533)

Glucose/galactose selectively alters ISG protein not RNA levels in interferon-primed cells. by Tyron Chang (9922533)

Glucose but not galactose culturing of IFN-γ primed cells reduces VACV and HSV-1 replication. by Tyron Chang (9922533)

Layout of the locations of the four pens (two shaded, two unshaded), the water through (“W”), the shaded automatic feeders (two per pen) and the shade structures in a feedlot syste... by M. Jordana Rivero (14610947)

Subjects:

Glucose/galactose regulation of IFN-γ induced IRF1 protein is conserved in mammals. by Tyron Chang (9922533)

<i>IRF1</i> impacts VACV replication in glucose/IFN-γ primed but not galactose conditions. by Tyron Chang (9922533)

Primer sequences used for RT-PCR. by Jingjing Chen (293564)

“…Notably, SIRT1 levels decrease with age in both mice and during cellular senescence, highlighting its significance in anti-aging processes. …”

Experimental design used in broiler chickens. by Oumayma Arbani (21001472)

Subjects:

Microscopical lesions in trachea and lungs H&E staining on dpi 5. by Oumayma Arbani (21001472)

Subjects:

Downregulation of TRIM37 expression exacerbates pathological damage in the MS model. by Lai Jiang (2401513)

Subjects:

S1 Graphical - by Agnieszka Murawska (11021928)

Subjects:

Overexpression <i>TRIM37</i> promotes myelin repair and inhibits cell apoptosis by upregulating PEX5. by Lai Jiang (2401513)

Subjects:

Data. by Rim Kooli (15426816)

Subjects:

Primer sequences and information. by Lai Jiang (2401513)

Subjects:

The original plotting data. by Hongmei Qian (538647)

Subjects:

Identification of gene co-expression modules associated with MS. by Lai Jiang (2401513)

Subjects:

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”